Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Turning Point for Blood Products? Discussions on Basic Policy on Blood Law Moving Ahead
By Yoshinori Sagehashi The Pharmaceutical Affairs and Food Sanitation Council’s Committee on Blood Programs has been discussing systemic reforms that would drastically change the structure of the blood products industry. It is discussing the “basic policy” on the Blood Law,…
To read the full story
Related Article
- MHLW Approves Proposed Reforms to Allow the Export of Plasma Fraction Products
December 19, 2017
- MHLW Looks to Lift Ban on Exports of Plasma Fraction Products by FY2020
December 1, 2017
- MHLW Sets Out Plan to Ease Export Ban for Plasma Fraction Products
September 7, 2017
- MHLW Panel Recommends Moving Ahead with Discussions toward Easing Regulations on Export of Blood Products
June 16, 2017
- MHLW Panel Initiates Discussions on Whether to Lift Ban on Export of Blood Products
March 17, 2017
REGULATORY
- Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
- Japan Launches Task Force to Secure Critical Supplies amid Middle East Crisis
April 3, 2026
- MHLW Streamlines Lot Release Procedures for Vaccines, Blood Products
April 3, 2026
- MHLW Allows Outer Packaging Labeling for Regenerative Medicine Products
April 3, 2026
- MHLW’s Drug Supply Monitoring System Now Up and Running
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…